Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0777
    -0.0016 (-0.15%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    +0.0002 (+0.02%)
     
  • USD/JPY

    151.3460
    -0.0260 (-0.02%)
     
  • Bitcoin USD

    69,929.22
    -797.65 (-1.13%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Novavax Plans to Cut $50 Million in Costs, COVID-19 Vaccine Remains Only Marketed Product

  • Novavax Inc's (NASDAQ: NVAX) CEO, newly appointed CEO John Jacobs, said the company would cut about $50 million in costs in Q1 of 2023 and plans further cuts.

  • "We're looking at everything from buildings, leases, land, headcount, and contractors, every aspect of our company and the way we work," Jacobs said in an interview with Reuters.

  • Jacobs also said the company is in regular talks with the FDA over the potential design of its 2023 COVID-19 booster shot and believes Novavax will have a new shot ready in time for the fall.

  • The company appointed John Jacobs, President & CEO following the retirement of Stanley Erck, who served as President & CEO for 12 years.

  • Also Read: FDA's Regulatory Delay is The Reason For Novavax, Lucira Health's Failure

  • Novavax's COVID-19 vaccine is its only marketed product after 35 years in business, the report added.

  • The CEO added that the company did not expect to launch its individual flu vaccine this year and will focus on the COVID vaccine.

  • Jacobs said Novavax would seek funding for its COVID/influenza combination shot, depending on whether the upcoming data is positive.

  • In February, when the company released its fiscal 2022 earnings, it said, "substantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued."

  • Novavax's Q4 revenue increased 61% year-over-year to $357 million, which missed average analyst estimates of $383.14 million.

  • In its 10K filing, the company said the U.S. government did not extend its agreement with Novavax beyond December 2023, putting some of the remaining $416 million in that deal at risk.

  • Novavax also said that depending on the outcome of its arbitration with Gavi, it could be required to refund all or a portion of the $697.4 million it received from the group.

  • Price Action: NVAX shares are up 1.44% at $9.16 during the premarket session on the last check Thursday.

  • Photo by Jernej Furman via Flickr

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Novavax Plans to Cut $50 Million in Costs, COVID-19 Vaccine Remains Only Marketed Product originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement